Arena Pharmaceuticals, Inc. Message Board

  • malph_ralph@rocketmail.com malph_ralph Mar 20, 2013 7:47 PM Flag

    Comparing VVUS and their lacklustre sales and Belviq is the biggest joke of all

    Its done consistently to fulfill agendas in endless "articles" but its too ridiculous. Q cannot even be prescribed to women aged 16 to 45. It is restricted to mail order, that alone restricts is potential let alone the safety. Belviq will be readily available to all who need it, with a strong marketing team and budget. Wait until this launches, if a small fraction of the market is prescribed Belviq the cash flow is phenomenal. And way above what Q can ever reach on availability, accessibility and safety issues alone. Belviq is the clear winner with or without Europe. China is a major market for Belviq in the years to come and that's a shoe in for approval.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
ARNA
7.98-0.02(-0.25%)May 17 4:00 PMEDT